ALIGN TECHNOLOGY INC SEC Filings

Align Technology, Inc. is reported to have 5.4% of its Common Stock beneficially owned by a group of related trusts and individuals led by members of the Gund family. The group reports beneficial ownership of 3,812,981 shares based on 71,039,852 shares outstanding as of July 31, 2026.

Within the group, G. Zachary Gund may be deemed to own 1,875,147 shares (2.6% of the class) and Grant Gund 1,435,981 shares (2.0%), mainly through multiple trusts and LLCs where they act as trustee, manager, or co‑manager. Several additional trusts and the Gordon & Llura Gund Foundation each report smaller fractional percentages, with varying sole or shared voting and dispositive powers.

FMR LLC filed as a significant holder of Align Technology common stock, reporting 4,060,032.23 shares beneficially owned as of June 30, 2026. This position represents 5.7% of the outstanding common stock.

FMR LLC reports sole dispositive power over 4,060,032.23 shares and sole voting power over 4,008,802.08 shares, with no shared voting or dispositive power. Abigail P. Johnson is also listed as a reporting person with sole dispositive power over the same 4,060,032.23 shares, but no voting power. One or more other persons may receive dividends or sale proceeds from these shares, but no such person has more than 5% of the class.

Align Technology reported net revenues of $1,056.2 million for the quarter ended June 30 2026, up 4.3% year over year. Clear Aligner revenues rose to $870.9 million, while Systems and Services declined to $185.3 million. Income from operations was $154.0 million, an operating margin of 14.6%, and net income was $108.3 million, or $1.51 per diluted share. The effective tax rate was 27.2%.

For the first six months of 2026, net revenues reached $2,096.3 million and net income $221.1 million. Operating cash flow was $343.8 million, with cash and cash equivalents of $1,102.6 million at June 30 2026. The company invested in growth and capacity, including capital expenditures and a planned $200 million manufacturing facility in Hyderabad, India expected to start operations in 2027, while repurchasing about 0.4 million shares for $66.7 million. Results were affected by $69.3 million in legal settlements and contingencies for the first half, accelerated depreciation of $15.6 million tied to prior restructuring, and an accrued $37.5 million UK VAT liability following an adverse tribunal decision, even as the company recorded favorable outcomes in certain patent and antitrust litigations.

Align Technology, Inc. announced a set of governance, strategic, and capital-allocation initiatives intended to support long-term growth and shareholder value. Following discussions with Elliott Investment Management, the company plans to appoint three new independent directors to its Board, focusing on candidates with healthcare, medical device, technology, and global operations experience.

Align has begun a comprehensive strategic and operating model review with a global consulting firm, aimed at strengthening commercial execution, organizational effectiveness, resource optimization, and scalability, with the goal of supporting sustainable revenue growth and margin expansion. The company increased its 2026 share repurchase commitment and now intends to repurchase $400 million to $500 million of common stock during 2026. Align reports over 302.0 thousand doctor customers, a 600 million consumer market opportunity, and approximately 23.5 million patients treated with Invisalign over 29 years.

Align Technology reported record Q2 2026 revenue of $1,056.2 million, up 4.3% year-over-year and 1.5% sequentially. Clear Aligner revenue was $870.9 million, up 8.2% year-over-year on record shipments of 691.8 thousand cases, while Imaging Systems and CAD/CAM Services revenue was $185.3 million, down 10.8% year-over-year.

GAAP gross margin was 71.7% and operating margin 14.6%; on a non-GAAP basis, gross margin was 72.3% and operating margin 22.9%. GAAP net income was $108.3 million, or $1.51 per diluted share, and non-GAAP diluted EPS was $2.64. Cash and cash equivalents were $1,102.6 million, with six‑month operating cash flow of $343.8 million. The company repurchased about 393.4 thousand shares for approximately $67 million and plans total 2026 repurchases of $400–$500 million. Align recorded an estimated $37.5 million UK VAT liability and will begin charging 20% UK VAT on applicable products from September 7, 2026. Management expects Q3 2026 revenue of $1.00–$1.02 billion and continues to target 3–4% full‑year 2026 revenue growth with higher GAAP and non-GAAP operating margins versus 2025.

Align Technology, Inc. reported that Julie Coletti, its Executive Vice President and Chief Legal and Regulatory Officer, has resigned to join Illumina, Inc. as Chief Legal Officer. The company states that her resignation was submitted on July 6, 2026 and will be effective August 1, 2026.

The filing does not describe any dispute or disagreement, indicating the change is related to Ms. Coletti’s decision to take a new role at another company.

Align Technology, Inc. announced a planned Board leadership transition. C. Raymond Larkin, Jr. will retire as Chairman of the Board effective July 1, 2026, after more than 20 years of service, and will remain on the Board and the Nominating and Governance Committee through December 31, 2026. His decision to step down from the Board is stated as not due to any disagreement with the company’s operations, policies, or practices.

The Board has appointed Kevin Conroy, an independent director since December 2023 and Chair of the Compensation and Human Capital Committee since January 2026, to become Chairman effective July 1, 2026. The company highlights his prior leadership at Exact Sciences and ongoing board role at Abbott Laboratories as relevant experience for Align’s next phase of growth and innovation in digital dentistry.

ALIGN TECHNOLOGY INC director Britt J. Vitalone reported routine equity compensation activity. On May 20, 2026, 100% of previously granted restricted stock units vested, and 1,443 shares of common stock were delivered, leaving the same number of shares held directly.

On the same date, Vitalone received a new grant of 1,836 restricted stock units, which will vest on the earlier of May 20, 2027 or the next annual stockholder meeting, assuming continued service. The filing shows only acquisitions through RSU vesting and grant, with no open-market purchases or sales.

ALIGN TECHNOLOGY INC director Susan E. Siegel reported routine equity compensation activity. She exercised previously granted restricted stock units, receiving 1,745 shares of common stock, bringing her direct holdings to 10,723 shares after the transactions.

She was also granted 1,836 new restricted stock units tied to common stock. These RSUs will fully vest on the earlier of May 20, 2027 or the date of the next annual meeting of stockholders, with shares delivered on that vesting date assuming her continued service.